Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.
Non-clinical research has been published about roginolisob, iOnctura’s non-ATP competitive alloseteric modulator of PI3Kδ, for the potential treatment of patients with solid and hematological tumors.